Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of NZ-687 in patients with cancer pain
jRCT2080224082Phase 3Completed
- Sponsor
- Nippon Zoki Pharmaceutical
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tramadol in cancer pain (2 arms), sponsored by Nippon Zoki Pharmaceutical. Primary endpoint: Change in VAS pain score at rest. Started Oct 2018; status: completed.
02
Drugs
tramadol
03
Conditions
cancer pain
Beyond the preview
Go deeper on jRCT2080224082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224082.